Evidence map›Paper›PMID 33314465›Full record

ArticlePsychiatry and clinical neurosciences2021

Recent updates of eye movement abnormalities in patients with schizophrenia: A scoping review.

Alexandra Wolf, Kazuo Ueda, Yoji Hirano

2 registry-linked trialsOpen access · hybridAbstract readScoping Review
In one paragraph

Article in Psychiatry and clinical neurosciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 47 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 1 pooled it
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07057024 naactive not recruitingnot on this mapstarted 2026, after this paper: background citation

Contribution of Virtual Reality Eye Tracking in the Identification of Schizophrenia, Bipolar and Depression

TypeinterventionalSponsorEtablissement Public de Santé Barthélemy DurandRan2026 to 2029Enrolled120ConditionsPsychiatric Disorders (Diagnosis)ArmsClinical and eye movements
NCT07702526 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

Effects of an Eye-Movement Intervention on Cognitive Impairment in Individuals Across Illness Stages of Schizophrenia: Protocol for a Stratified Randomized, Active-Controlled, Assessor-Blinded Trial

TypeinterventionalSponsorShanghai Mental Health CenterRan2026 to 2028Enrolled160ConditionsSchizophrenia, Cognitive Impairment, Clinical High Risk for PsychosisArmsEye-Movement Training, Finger-Controlled Game Training
3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Alexandra WolfInternational Research Fellow of Japan Society for the Promotion of Science, Fukuoka, Japan.ORCID https://orcid.org/0000-0002-0795-0258
Kazuo UedaDepartment of Human Science, Research Center for Applied Perceptual Science, Kyushu University, Fukuoka, Japan.ORCID https://orcid.org/0000-0002-1885-0463
Yoji HiranoDepartment of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.ORCID https://orcid.org/0000-0001-6847-9677
Kyushu University · JP

Funding

Japan Society for the Promotion of Science JP 15K09836 (YH)Japan Society for the Promotion of Science JP 18K07604 (YH)Japan Society for the Promotion of Science JP 19F19307 (AW)Japan Society for the Promotion of Science JP 19H03579 (YH)Japan Society for the Promotion of Science JP 20KK0193 (YH)Schizophrenia International Research Society
6 · The paper itself

Abstract

aimAlthough eye-tracking technology expands beyond capturing eye data just for the sole purpose of ensuring participants maintain their gaze at the presented fixation cross, gaze technology remains of less importance in clinical research. Recently, impairments in visual information encoding processes indexed by novel gaze metrics have been frequently reported in patients with schizophrenia. This work undertakes a scoping review of research on saccadic dysfunctions and exploratory eye movement deficits among patients with schizophrenia. It gathers promising pieces of evidence of eye movement abnormalities in attention-demanding tasks on the schizophrenia spectrum that have mounted in recent years and their outcomes as potential biological markers.

methodsThe protocol was drafted based on PRISMA for scoping review guidelines. Electronic databases were systematically searched to identify articles published between 2010 and 2020 that examined visual processing in patients with schizophrenia and reported eye movement characteristics as potential biomarkers for this mental illness.

resultsThe use of modern eye-tracking instrumentation has been reported by numerous neuroscientific studies to successfully and non-invasively improve the detection of visual information processing impairments among the screened population at risk of and identified with schizophrenia.

conclusionsEye-tracking technology has the potential to contribute to the process of early intervention and more apparent separation of the diagnostic entities, being put together by the syndrome-based approach to the diagnosis of schizophrenia. However, context-processing paradigms should be conducted and reported in equally accessible publications to build comprehensive models.

Indexed as

Eye-Tracking TechnologyAttentionCognitive DysfunctionEye MovementsHumansSchizophreniaVisual Perceptionbiomarkereye-tracking dysfunctiongaze metrics parametersschizophreniavisual information processing

Identifiers

PMID33314465
PMCPMC7986125
OpenAlexW3110824040

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.